Eiffage Selected FINALCAD As a Strategic Partner to Accelerate Digital Transformation of Its Construction Sites
19.6.2017 19:26:00 EEST | Business Wire | Press release
Eiffage selected FINALCAD as a strategic partner to accelerate the digital transformation of the construction sites of the Group, in an open innovation approach.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170619005968/en/
Benoit de Ruffray, Chairman and CEO, Eiffage with FINALCAD co-founders Jimmy Louchart, Joffroy Louchart and David Vauthrin. Photo credit : Alejandra Gomez. (Photo: Business Wire)
The digital transformation of the construction industry has turned into a strategic dimension for the performance of companies in this space. It is a driver of , productivity gains and quality improvement for the construction and infrastructure projects.
Aware of the quick changes happening in the digitalisation ecosystem of the construction industry, Eiffage has taken a stance to adopt a partnership approach with innovative start-ups. Such partnerships provide the Group with a better agility and direct access to the expertise of these innovative companies, often several years worth of investment in Research & Development.
“We selected FINALCAD because their approach to the field is different from other players in the market, and their product has received positive feedback from users on the field. This strong partnership is based on an open, two-sided innovation model. FINALCAD needs Eiffage to grow even stronger, and Eiffage needs FINALCAD to accelerate” said Benoît de Ruffray, Chairman and CEO, Eiffage.
The initial objective of the Group was to digitise two thirds of Eiffage Construction projects with FINALCAD by 2018. This objective has already been reached to date, demonstrating very strong adoption by the field, beyond expectations. Other branches of the Group have also started their digitisation with FINALCAD.
“FINALCAD was successfully used on projects of the Eiffage Group since 2012, but was limited to a project-based approach. From now on, we will accompany Eiffage in an enterprise-wide digital transformation, opening new perspectives in analytics for driving activity performance” said Jimmy Louchart, co-founder and CEO, FINALCAD. “From our point of view, the stance that Eiffage has taken with this partnership to accelerate their digital transformation is a clear demonstration of being an agile player and forerunner in France and in the world.”
About Eiffage
Eiffage is one of Europe's leading construction and concessions companies. The Group's activities are organised on the basis of the following business lines: construction, real estate, regional development, civil engineering, metal, roads, energy and concessions. Thanks to the experience of more than 63,000 employees, Eiffage generated revenues of €14 billion in 2016, including nearly 20% outside France.
About FINALCAD
FINALCAD is a global leader in field mobile apps and predictive analytics for construction, infrastructure, energy and concessions. It helps contractors, developers, architects and field operators with quality control, defect management and progress monitoring, during construction and facility management. Since 2011, FINALCAD has been delivering more than 15,000 projects in 35 countries, and has secured over $22 million in funding from investors including Serena Capital, Aster Capital, and CapHorn Invest.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170619005968/en/
Contact information
Eiffage
Sophie Mairé
+ 33 (0) 1 71 59 10 62
sophie.maire@eiffage.com
or
FINALCAD
Aurélien
Blaha
+33 (0) 6 23 99 92 99
aurelien@finalcad.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom